Dendrimer-based Nanoparticle for Dye Sensitized Solar Cells with Improved Efficiency

Dye sensitized solar cells were fabricated with DyLight680 (DL680) dye and its corresponding europium conjugated dendrimer, DL680-Eu-G5PAMAM, to study the effect of europium on the current and voltage characteristics of the DL680 dye sensitized solar cell. The dye samples were characterized by using Absorption Spectroscopy, Emission Spectroscopy, Fluorescence lifetime and Fourier Transform Infrared measurements. Transmission electron microscopy imaging was carried out on the DL680-Eu-G5PAMAM dye and DL680-Eu-G5PAMAM dye sensitized titanium dioxide nanoparticles to analyze the size of the dye molecules and examine the interaction of the dye with titanium dioxide nanoparticles. The DL680-Eu-G5PAMAM dye sensitized solar cells demonstrated an enhanced solar-to-electric energy conversion of 0.32% under full light illumination (100 mWcm−2, AM 1.5 Global) in comparison with that of DL680 dye sensitized cells which recorded an average solar-to-electric energy conversion of only 0.19%. The improvement of the efficiency could be due to the presence of the europium that enhances the propensity of dye to absorb sunlight

Synthesis and characterization of reduced graphene oxide and their application in dye-sensitized solar cells

Reduced graphene oxide has certain unique qualities that make them versatile for a myriad of applications. Unlike graphene oxide, reduced graphene oxide is a conductive material and well suited for use in electrically conductive materials, such as solar cell devices. In this study, we report on the synthesis of graphene oxide as well as the fabrication and characterization of dye-sensitized solar cells with a photoanode which is an amalgam of reduced graphene oxide and titanium dioxide. The synthesized reduced graphene oxide and the corresponding photoanode were fully characterized using Ultraviolet-visible, Fourier transform infrared (FTIR), and Raman Spectrometry. The morphology of the sample was assessed using Atomic Force Microscopy, Field Emission Scanning Electron Microscopy, Transmission Electron Microscopy, and Energy Dispersive X-ray Spectroscopy. The photovoltaic characteristics were determined by photocurrent and photo-voltage measurements of the fabricated solar cells. The electrical impedances of both sets of devices were also evaluated. Overall, the solar to electric power efficiency of the device with reduced graphene oxide was observed to be higher (2.02%) than the device without the reduced graphene oxide (1.61%)

Synthesis and Characterization of Reduced Graphene Oxide and Their Application in Dye-Sensitized Solar Cells

Reduced graphene oxide has certain unique qualities that make them versatile for a myriad of applications. Unlike graphene oxide, reduced graphene oxide is a conductive material and well suited for use in electrically conductive materials, such as solar cell devices. In this study, we report on the synthesis of graphene oxide as well as the fabrication and characterization of dye-sensitized solar cells with a photoanode which is an amalgam of reduced graphene oxide and titanium dioxide. The synthesized reduced graphene oxide and the corresponding photoanode were fully characterized using Ultraviolet-visible, Fourier transform infrared (FTIR), and Raman Spectrometry. The morphology of the sample was assessed using Atomic Force Microscopy, Field Emission Scanning Electron Microscopy, Transmission Electron Microscopy, and Energy Dispersive X-ray Spectroscopy. The photovoltaic characteristics were determined by photocurrent and photo-voltage measurements of the fabricated solar cells. The electrical impedances of both sets of devices were also evaluated. Overall, the solar to electric power efficiency of the device with reduced graphene oxide was observed to be higher (2.02%) than the device without the reduced graphene oxide (1.61%)

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Background: Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for neovascular age-related macular degeneration (nAMD). Methods: TENAYA and LUCERNE were randomised, double-masked, non-inferiority trials across 271 sites worldwide. Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1:1) to intravitreal faricimab 6·0 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2·0 mg every 8 weeks. Randomisation was performed through an interactive voice or web-based response system using a stratified permuted block randomisation method. Patients, investigators, those assessing outcomes, and the funder were masked to group assignments. The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. These trials are registered with ClinicalTrials.gov (TENAYA NCT03823287 and LUCERNE NCT03823300). Findings: Across the two trials, 1329 patients were randomly assigned between Feb 19 and Nov 19, 2019 (TENAYA n=334 faricimab and n=337 aflibercept), and between March 11 and Nov 1, 2019 (LUCERNE n=331 faricimab and n=327 aflibercept). BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [-1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [-1·7 to 1·8]). Rates of ocular adverse events were comparable between faricimab and aflibercept (TENAYA n=121 [36·3%] vs n=128 [38·1%], and LUCERNE n=133 [40·2%] vs n=118 [36·2%]). Interpretation: Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD